Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Description

This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.

Conditions

Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.

Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Condition
Ovarian High Grade Serous Adenocarcinoma
Intervention / Treatment

-

Contacts and Locations

Atlanta

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States, 30322

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy
  • * Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • * There will be no limitations on number of prior lines of therapy
  • * Trial is open to non-English speaking patients
  • * Trial is open to patients referred from community practice
  • * Patients who are \< 18 years old
  • * Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive)
  • * Patients who are incarcerated
  • * Patients who are unable to provide consent / lack decision-making capacity

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Emory University,

Namita Khanna, MD, MSPH, PRINCIPAL_INVESTIGATOR, Emory University Hospital/Winship Cancer Institute

Study Record Dates

2026-06-30